Selnoflast monopotassium
Based on 1 publication(s) in Google Scholar
Selnoflast (RO7486967) monopotassium, formerly somalix/RG6418/IZD334 monopotassium, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast monopotassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast monopotassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease.
For research use only. We do not sell to patients.
- CAS No.: 2260969-37-5
- Formula: C20H28KN3O3S
- Molecular Weight:429.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Selnoflast monopotassium
More
Biological Activity
|
NLRP3 |
Chemical Information
-
CAS No. 2260969-37-5
-
Molecular Weight 429.62
-
Formula C20H28KN3O3S
-
SMILES
O=C([N-]S(=O)(C1CCN(CC)CC1)=O)NC2=C(CCC3)C3=CC4=C2CCC4.[K+]
-
Synonyms
Somalix monopotassium; RO-7486967 monopotassium; IZD334 monopotassium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Chem Biol
Interrogating direct NLRP3 engagement and functional inflammasome inhibition using cellular assays. [Abstract]2024 Feb 15;31(2):349-360.e6. PMID: 37858335
Purity & Documentation
References
[1]. Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13(11):e1471. [Content Brief]
[2]. Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29. [Content Brief]
[3]. Silvis MJM, et al., NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction. Biomedicines. 2022 Nov 28;10(12):3056. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Selnoflast monopotassium Related Classifications
HY-132831C Related Classifications
Powered by Bioz
- Selnoflast monopotassium
- 2260969-37-5
- Somalix monopotassium
- RO-7486967 monopotassium
- IZD334 monopotassium
- NOD-like Receptor (NLR)
- Interleukin Related
- orally active
- reversible
- NLRP3 inhibitor
- IL-1β inhibitor
- Alzheimer's disease
- ulcerative colitis
- chronic obstructive pulmonary disease
- macrophages
- Inhibitor
- inhibitor
- inhibit